Int J Oral Max Surg: ACTN4基因扩增在I、II期舌癌预后中的意义

2017-09-24 MedSci MedSci原创

尽管早期舌癌可通过部分切除术彻底切除,但也经常观察到晚期颈淋巴结转移。

尽管早期舌癌可通过部分切除术彻底切除,但也经常观察到晚期颈淋巴结转移。 ACTN4(蛋白质名称:actinin-4)基因扩增与各种癌症的转移潜能密切相关。该回顾性研究调查了ACTN4基因扩增作为I / II期舌癌预后生物标志物的潜在用途。根据肿瘤标志物预后研究(REMARK)指南的报告建议,回顾性地纳入了54例I / II期舌癌患者。通过荧光原位杂交(FISH)和免疫组化(IHC)分别评估ACTN4的拷贝数和肌动蛋白-4的蛋白表达。 ACTN4基因扩增患者的总生存时间明显短于无基因扩增的患者(P = 0.0010,log-rank检验)。 ACTN4基因扩增是I / II期舌癌患者死亡的重要的独立危险因素(风险比6.08,95%;置信区间1.66-22.27)。ACTN4基因扩增是舌癌总体生存时间的潜在预后生物标志物。

原始出处:

T. Kakuya, T. Mori, S. Yoshimoto, et al. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. International Journal of Oral and Maxillofacial Surgery. 2017 August. doi: 10.1016/j.ijom.2017.03.001

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721598, encodeId=82931e21598c1, content=<a href='/topic/show?id=f73a86563eb' target=_blank style='color:#2F92EE;'>#舌癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86563, encryptionId=f73a86563eb, topicName=舌癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6e333038842, createdName=medsci257, createdTime=Thu Mar 01 03:51:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020250, encodeId=dc4c2020250a7, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 03 17:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247288, encodeId=a57124e288ee, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Sep 24 12:30:35 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247279, encodeId=3ed624e279c6, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Sep 24 12:28:05 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-03-01 medsci257
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721598, encodeId=82931e21598c1, content=<a href='/topic/show?id=f73a86563eb' target=_blank style='color:#2F92EE;'>#舌癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86563, encryptionId=f73a86563eb, topicName=舌癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6e333038842, createdName=medsci257, createdTime=Thu Mar 01 03:51:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020250, encodeId=dc4c2020250a7, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 03 17:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247288, encodeId=a57124e288ee, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Sep 24 12:30:35 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247279, encodeId=3ed624e279c6, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Sep 24 12:28:05 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-04-03 小几洁
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721598, encodeId=82931e21598c1, content=<a href='/topic/show?id=f73a86563eb' target=_blank style='color:#2F92EE;'>#舌癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86563, encryptionId=f73a86563eb, topicName=舌癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6e333038842, createdName=medsci257, createdTime=Thu Mar 01 03:51:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020250, encodeId=dc4c2020250a7, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 03 17:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247288, encodeId=a57124e288ee, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Sep 24 12:30:35 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247279, encodeId=3ed624e279c6, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Sep 24 12:28:05 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 Y—xianghai

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1721598, encodeId=82931e21598c1, content=<a href='/topic/show?id=f73a86563eb' target=_blank style='color:#2F92EE;'>#舌癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86563, encryptionId=f73a86563eb, topicName=舌癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6e333038842, createdName=medsci257, createdTime=Thu Mar 01 03:51:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020250, encodeId=dc4c2020250a7, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 03 17:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247288, encodeId=a57124e288ee, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Sep 24 12:30:35 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247279, encodeId=3ed624e279c6, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Sep 24 12:28:05 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0